{"id":42569,"date":"2025-09-30T16:36:26","date_gmt":"2025-09-30T08:36:26","guid":{"rendered":"https:\/\/flcube.com\/?p=42569"},"modified":"2025-09-30T16:36:27","modified_gmt":"2025-09-30T08:36:27","slug":"c%e2%80%91mer-medical-gilead-and-hanmi-sign-global-licensing-deal-for-first%e2%80%91in%e2%80%91class-p%e2%80%91glycoprotein-inhibitor-encequidar","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42569","title":{"rendered":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar"},"content":{"rendered":"\n<p><strong>C\u2011MER Medical Holdings Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/3309:HKG\">HKG: 3309<\/a>)<\/strong> announced that its joint\u2011venture arm, <strong>Health Hope Pharma Limited (HHP)<\/strong>, has entered into a tri\u2011partite global licensing and collaboration agreement with <strong>Gilead Sciences, Inc.<\/strong> and <strong>Hanmi Pharm. Co., Ltd.<\/strong> The deal centers on <strong>encequidar<\/strong>, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Virology Rights<\/strong> \u2013 HHP and Hanmi grant Gilead the worldwide exclusive rights to encequidar for virology indications.<\/li>\n\n\n\n<li><strong>Supply &amp; Technical Collaboration<\/strong> \u2013 The partners will provide drug supply, share technical know\u2011how, and serve as key project collaborators.<\/li>\n\n\n\n<li><strong>Financial Terms<\/strong> \u2013 HHP receives an upfront payment of <strong>USD\u202f10\u202fmillion<\/strong>, with potential future payments of up to <strong>USD\u202f72.5\u202fmillion<\/strong> and low single\u2011digit royalties on net sales, contingent on milestone achievements.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Paclitaxel Transformation<\/strong> \u2013 Encequidar, originally developed by Hanmi, enables the conversion of injectable paclitaxel into an oral regimen.<\/li>\n\n\n\n<li><strong>Phase\u202fIII Trial<\/strong> \u2013 HHP is preparing a global, multi\u2011center Phase\u202fIII trial of oral paclitaxel plus encequidar for metastatic breast cancer, targeting U.S., Hong Kong, and New\u202fZealand markets by 2025.<\/li>\n\n\n\n<li><strong>Chemotherapy Innovation<\/strong> \u2013 The trial aims to replace intravenous paclitaxel with an oral formulation, potentially improving patient convenience and adherence.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h3>\n\n\n\n<p>The collaboration positions Gilead to leverage a novel virology\u2011specific P\u2011gp inhibitor, while C\u2011MER and Hanmi expand their portfolio into oncology. If the Phase\u202fIII trial demonstrates superior efficacy or safety, the oral paclitaxel\u2011encequidar combination could disrupt the breast\u2011cancer chemotherapy landscape and generate significant revenue for all parties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[4377,16,226,261,2564],"class_list":["post-42569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-cmer-medical","tag-cancer","tag-gilead-sciences","tag-hanmi-pharmaceutical","tag-hkg-3309"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42569\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar\" \/>\n<meta property=\"og:description\" content=\"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42569\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-30T08:36:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-30T08:36:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar\",\"datePublished\":\"2025-09-30T08:36:26+00:00\",\"dateModified\":\"2025-09-30T08:36:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3011.webp\",\"keywords\":[\"C\u2011MER Medical\",\"Cancer\",\"Gilead Sciences\",\"Hanmi Pharmaceutical\",\"HKG: 3309\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42569#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42569\",\"name\":\"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3011.webp\",\"datePublished\":\"2025-09-30T08:36:26+00:00\",\"dateModified\":\"2025-09-30T08:36:27+00:00\",\"description\":\"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42569\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3011.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3011.webp\",\"width\":1080,\"height\":608,\"caption\":\"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar - Insight, China&#039;s Pharmaceutical Industry","description":"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42569","og_locale":"en_US","og_type":"article","og_title":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar","og_description":"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.","og_url":"https:\/\/flcube.com\/?p=42569","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-30T08:36:26+00:00","article_modified_time":"2025-09-30T08:36:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42569#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42569"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar","datePublished":"2025-09-30T08:36:26+00:00","dateModified":"2025-09-30T08:36:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42569"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","keywords":["C\u2011MER Medical","Cancer","Gilead Sciences","Hanmi Pharmaceutical","HKG: 3309"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42569#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42569","url":"https:\/\/flcube.com\/?p=42569","name":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42569#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","datePublished":"2025-09-30T08:36:26+00:00","dateModified":"2025-09-30T08:36:27+00:00","description":"C\u2011MER Medical Holdings Limited (HKG: 3309) announced that its joint\u2011venture arm, Health Hope Pharma Limited (HHP), has entered into a tri\u2011partite global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharm. Co., Ltd. The deal centers on encequidar, a first\u2011in\u2011class P\u2011glycoprotein (P\u2011gp) inhibitor that can convert injectable therapeutics into oral formulations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42569"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42569#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","width":1080,"height":608,"caption":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"C\u2011MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First\u2011In\u2011Class P\u2011glycoprotein Inhibitor Encequidar"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3011.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42569"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42569\/revisions"}],"predecessor-version":[{"id":42572,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42569\/revisions\/42572"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42571"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}